---
title: "Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292794533.md"
description: "Abbott Laboratories (ABT) reports Q2 earnings on July 15, with analysts expecting EPS of $1.28 (+1.6%) and revenue of $12.52B (+12.4%). Growth is driven by the Exact Sciences acquisition, particularly its CancerGuard test. While Seeking Alpha rates ABT a Buy based on long-term MCED potential, Baird models more modest comparable growth of 4-4.5% for Q2. Despite beating estimates historically, ABT's stock has declined 29% year-to-date."
datetime: "2026-07-15T16:01:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292794533.md)
  - [en](https://longbridge.com/en/news/292794533.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292794533.md)
---

# Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition


### Related Stocks

- [EXAS.US](https://longbridge.com/en/quote/EXAS.US.md)
- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)

## Related News & Research

- [23:20 ETPRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records](https://longbridge.com/en/news/293695963.md)
- [Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades](https://longbridge.com/en/news/293449087.md)
- [Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall](https://longbridge.com/en/news/293792909.md)
- [These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results](https://longbridge.com/en/news/293046426.md)
- [Key facts: Abbott completes TECTONIC IVL; closes Exact; raises guidance](https://longbridge.com/en/news/292999283.md)